Creating tiny particles to improve cancer immunotherapy
Development of Lipid Nanoparticles for B-cell Mediated Immunotherapies
['FUNDING_OTHER'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-10949080
This study is exploring a new way to use tiny particles to help cancer treatments work better by delivering medicine directly to tumors while protecting healthy cells, making it a promising option for patients undergoing B-cell immunotherapy.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10949080 on ClinicalTrials.gov |
What this research studies
This research focuses on developing lipid nanoparticles that can enhance the effectiveness of B-cell mediated immunotherapies for cancer treatment. By engineering these nanoparticles to specifically target tumor tissues, the goal is to improve drug delivery while minimizing damage to healthy cells. The approach involves using a layer-by-layer assembly method to create nanoparticles that can carry various therapeutic agents, potentially leading to better treatment outcomes for patients. This innovative method aims to overcome limitations associated with traditional drug delivery systems, particularly those that rely on polyethylene glycol.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer who may benefit from enhanced immunotherapy approaches.
Not a fit: Patients with non-cancerous conditions or those whose cancer types are not targeted by this nanoparticle technology may not receive any benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments with fewer side effects.
How similar studies have performed: Previous research has shown promise in using nanoparticles for drug delivery in cancer treatment, indicating a potential for success with this novel approach.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUSIN PIRES, IVAN — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: SUSIN PIRES, IVAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug, anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy